Daré Bioscience Reports Additional Results from Exploratory P-IIb Study (RESPOND) of Sildenafil for Female Sexual Arousal Disorder
Shots:
- The company highlighted an additional result from the exploratory P-IIb study (RESPOND) evaluating Sildenafil cream (3.6%) vs PBO in patients with FSAD
- The exploratory EP showed a significant improvement from baseline to the 8wk. after randomization in women in the ITT population, improvement in arousal lubrication, orgasm, and sexual desire were seen at 8wk. persisted through 12wks. post-randomization
- Sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor is currently marketed under the brand name Viagra for erectile dysfunction in men. Additional data support continued clinical development of Sildenafil cream for FSAD and/or female sexual interest/arousal disorder
Ref: Globe Newswire | Image: Dare Bioscience
Related News:- Daré’s Xaciato (clindamycin phosphate) Vaginal Gel Receives the US FDA’s Approval for the Treatment of Bacterial Vaginosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
